Abstract
Gastric cancer is a complex disease and the third leading cause of cancer deaths worldwide. To date, surgery remains the only curative strategy in locally advanced gastric cancer (LAGC) patients (pt), although the results of the MAGIC trial supported the implementation of a perioperative treatment (ttx) with epirubicin-cisplatin-5FU (ECF). Since 2019, the FLOT4-AIO trial showed that perioperative 5FU-leucovorin-oxaliplatin-docetaxel (FLOT) improved median overall survival (mOS) compared to ECF. We aimed to assess outcome differences in a non-clinical trial scenario in our LAGC cohort, according to multidisciplinary management in a highly specialized gastro-esophageal cancer functional unit (UFEG) integrating different specialists.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
